EP0433371A4 - Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof - Google Patents

Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof

Info

Publication number
EP0433371A4
EP0433371A4 EP19890910526 EP89910526A EP0433371A4 EP 0433371 A4 EP0433371 A4 EP 0433371A4 EP 19890910526 EP19890910526 EP 19890910526 EP 89910526 A EP89910526 A EP 89910526A EP 0433371 A4 EP0433371 A4 EP 0433371A4
Authority
EP
European Patent Office
Prior art keywords
protein
paramyxovirus
vaccine
production
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890910526
Other languages
English (en)
Other versions
EP0433371A1 (en
Inventor
Richard W. Compans
Ranjit Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Engineering Associates Ltd
Original Assignee
Molecular Engineering Associates Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Engineering Associates Ltd filed Critical Molecular Engineering Associates Ltd
Publication of EP0433371A1 publication Critical patent/EP0433371A1/en
Publication of EP0433371A4 publication Critical patent/EP0433371A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19890910526 1988-09-02 1989-08-29 Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof Withdrawn EP0433371A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24087788A 1988-09-02 1988-09-02
US240877 1988-09-02

Publications (2)

Publication Number Publication Date
EP0433371A1 EP0433371A1 (en) 1991-06-26
EP0433371A4 true EP0433371A4 (en) 1991-10-30

Family

ID=22908302

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890910526 Withdrawn EP0433371A4 (en) 1988-09-02 1989-08-29 Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof

Country Status (8)

Country Link
EP (1) EP0433371A4 (da)
JP (1) JPH04501058A (da)
AU (1) AU4314489A (da)
DK (1) DK37591D0 (da)
IL (1) IL91500A0 (da)
NZ (1) NZ230425A (da)
WO (1) WO1990002566A1 (da)
ZA (1) ZA896715B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE105334T1 (de) * 1988-04-22 1994-05-15 Upjohn Co Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
JP2649285B2 (ja) * 1990-11-29 1997-09-03 藤倉化成株式会社 ヒトパラインフルエンザ４ａ型ウイルスフュージョンプロテイン遺伝子及び該遺伝子を含む物質
NZ243611A (en) * 1991-07-17 1993-12-23 Commw Scient Ind Res Org Vaccine and its preparation for treating rhabdovirus and paramyxovirus
US5298239A (en) * 1991-10-07 1994-03-29 The Research Foundation Of State University Of New York Mutations rendering platelet glycoprotein IB α less reactive
US5317097A (en) * 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US5641751A (en) * 1995-05-01 1997-06-24 Centocor, Inc. Tumor necrosis factor inhibitors
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1836298B1 (en) 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
AU2006255122B2 (en) 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
DK2339014T3 (da) 2005-11-16 2015-07-20 Ambrx Inc Fremgangsmåder og sammensætninger omfattende ikke-naturlige aminosyrer
EP2064333B1 (en) 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
JP5399906B2 (ja) 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
US4847081A (en) * 1984-07-18 1989-07-11 W. R. Grace & Co.-Conn. Synthetic bovine parainfluenza viral proteins
JPS6226300A (ja) * 1984-10-10 1987-02-04 セントコ−・インコ−ポレ−テツド Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現

Also Published As

Publication number Publication date
EP0433371A1 (en) 1991-06-26
ZA896715B (en) 1990-09-26
JPH04501058A (ja) 1992-02-27
DK37591A (da) 1991-03-01
DK37591D0 (da) 1991-03-01
AU4314489A (en) 1990-04-02
WO1990002566A1 (en) 1990-03-22
NZ230425A (en) 1992-07-28
IL91500A0 (en) 1990-04-29

Similar Documents

Publication Publication Date Title
EP0433371A4 (en) Fusion protein of paramyxovirus, method of production using recombinant baculovirus expression vector, vaccine comprising such protein and use thereof
EP0324647A3 (en) Vector for the expression of fusion proteins and protein immunogens
IL94243A0 (en) Fusion polypeptide and its preparation
FI892208A7 (fi) Menetelmä ja välituote aggregoitumista ehkäisevien peptidien valmistamiseksi
EP0243929A3 (en) Polypeptide and protein derivatives and process for their preparation
EP0109942A3 (en) Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
ZA958659B (en) Production of peptides in plants as viral coat protein fusions
IL91843A0 (en) Hiv proteins and peptides useful in the diagnosis,prophylaxis aids or therapy of aids
GB2218421B (en) A process for producing envelope protein of japanese encephalitis virus using recombinant baculovirus; envelope proteins,recombinant baculovirus and vaccines
EP0491844A4 (en) Peptides including ctl epitopes of hiv proteins and use thereof
AU6428890A (en) Therapeutic peptides and proteins
EP0209543A4 (en) FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
EP0227110A3 (en) Human immunoglobulin g fc region protein and production thereof
PT85461A (en) Process for preparing recombinant htlv-iii proteins and uses thereof
IL91272A0 (en) Method for stabilizing heterologous protein expression and vectors for use therein
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
PL288140A1 (en) Polypeptide, vaccine, expression vector, method of immunizing human organisms, method of obtaining polypeptide and method of obtaining such vaccine and expression vector
ZA892518B (en) Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
AU3410889A (en) Novel recombinant vaccinia virus expression vectors and method of selecting same
IL89391A0 (en) Structural gene coding for an insecticidal endotoxin protein,said protein,its production and use of said gene and protein
IL86153A0 (en) Recombinant htlv-iii proteins and uses thereof
IL78314A0 (en) Expression vectors and methods for the production of recombinant human renin
GB2205568B (en) Recombinant plasmids and silk-like proteins produced therefrom
EP0423641A3 (en) Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha
FI870501A0 (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910910

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C07K 15/14

17Q First examination report despatched

Effective date: 19940420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19941101